Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C F Xu

Showing results (51-60 of 129) with videos related to

Pageof 13
Sort By:
American Journal of Human Genetics|September 1, 1990
Variation at the apolipoprotein (apo) AI-CIII-AIV gene cluster and apo B gene loci is associated with lipoprotein and apolipoprotein levels in Italian childrenC F Xu, M N Nanjee, J Savill, et al.
The Pharmacogenomics Journal|August 11, 2004
Identification of a pharmacogenetic effect by linkage disequilibrium mappingC-F Xu, K F Lewis, A J Yeo, et al.
Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica|January 1, 1993
[Effect of Equisetum hyemale on experimental hyperlipemia in rats and its toxic test]C F Xu, X Y Bian, S M Qu, et al.
Human Molecular Genetics|November 1, 1994
The detailed characterisation of a 400 kb cosmid walk in the BRCA1 region: identification and localisation of 10 genes including a dual-specificity phosphataseK A Jones, D M Black, M A Brown, et al.
Genes, Chromosomes & Cancer|February 1, 1997
Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer familiesC F Xu, J A Chambers, H Nicolai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 25, 2012
Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancerC F Xu, Z Xue, N Bing, et al.
The Pharmacogenomics Journal|December 3, 2003
A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemiaT M Danoff, D A Campbell, L C McCarthy, et al.
The Pharmacogenomics Journal|June 26, 2002
Linkage disequilibrium mapping identifies a 390 kb region associated with CYP2D6 poor drug metabolising activityL K Hosking, P R Boyd, C F Xu, et al.
British Journal of Cancer|April 15, 2010
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphismC-F Xu, B H Reck, Z Xue, et al.
Clinical Pharmacology and Therapeutics|October 1, 2010
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumorsB C Goh, N J Reddy, U B Dandamudi, et al.
Pageof 13

Showing results (51-60 of 129) with videos related to

Sort By:
Pageof 13
American Journal of Human Genetics|September 1, 1990
Variation at the apolipoprotein (apo) AI-CIII-AIV gene cluster and apo B gene loci is associated with lipoprotein and apolipoprotein levels in Italian childrenC F Xu, M N Nanjee, J Savill, et al.
The Pharmacogenomics Journal|August 11, 2004
Identification of a pharmacogenetic effect by linkage disequilibrium mappingC-F Xu, K F Lewis, A J Yeo, et al.
Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica|January 1, 1993
[Effect of Equisetum hyemale on experimental hyperlipemia in rats and its toxic test]C F Xu, X Y Bian, S M Qu, et al.
Human Molecular Genetics|November 1, 1994
The detailed characterisation of a 400 kb cosmid walk in the BRCA1 region: identification and localisation of 10 genes including a dual-specificity phosphataseK A Jones, D M Black, M A Brown, et al.
Genes, Chromosomes & Cancer|February 1, 1997
Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer familiesC F Xu, J A Chambers, H Nicolai, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 25, 2012
Concomitant use of pazopanib and simvastatin increases the risk of transaminase elevations in patients with cancerC F Xu, Z Xue, N Bing, et al.
The Pharmacogenomics Journal|December 3, 2003
A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemiaT M Danoff, D A Campbell, L C McCarthy, et al.
The Pharmacogenomics Journal|June 26, 2002
Linkage disequilibrium mapping identifies a 390 kb region associated with CYP2D6 poor drug metabolising activityL K Hosking, P R Boyd, C F Xu, et al.
British Journal of Cancer|April 15, 2010
Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphismC-F Xu, B H Reck, Z Xue, et al.
Clinical Pharmacology and Therapeutics|October 1, 2010
An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumorsB C Goh, N J Reddy, U B Dandamudi, et al.
Pageof 13